NEW YORK (GenomeWeb) – Precision for Medicine announced today that it has signed a binding agreement to acquire ACT Oncology, an oncology-focused contract research organization headquartered in Flemington, New Jersey.
Bethesda, Maryland-based Precision for Medicine provides tools and services that support research and clinical development of targeted therapies, diagnostics, clinical solutions, biomarker analytics, and regulatory guidance. ACT Oncology specializes in clinical trial design and execution.
"The acquisition of ACT Oncology represents a unique opportunity to provide our clients a completely novel solution to advance oncology research," Precision for Medicine President Chad Clark said in a statement. "With our combined infrastructure and expertise, we offer a true precision medicine research organization … and a truly unique offering for clients seeking advantages from early-stage, proof-of-concept programs to global registration studies."
The acquisition is expected to close within 30 days. Additional terms of the transaction were not disclosed.